EU Approval Nod Possible For Novartis, Gilead/Galapagos, and Janssen
CHMP Marketing Opinions Are Due On Alpelisib, Filgotinib, Ebola Vaccines
The May meeting of the European Medicines Agency’s drug evaluation committee, the CHMP, is under way. Decisions are due on whether eight marketing approval applications should be approved for marketing in the EU.
You may also be interested in...
A number of drug companies are set to learn the fate of their marketing authorization applications in the EU this week.
Applications to market Roche’s spinal muscular atrophy drug have already been submitted in eight countries including the US, where a decision is due in August.
Biocon is actively expanding its biosimilars manufacturing capacity with an aim to further penetrate EU markets after receiving a GMP approval for a key manufacturing site. The company has ramped up production for trastuzumab and pegfilgrastim, while awaiting approval for bevacizumab.